Monopar Therapeutics Statistics Share Statistics Monopar Therapeutics has 6.17M
shares outstanding. The number of shares has increased by 73.71%
in one year.
Shares Outstanding 6.17M Shares Change (YoY) 73.71% Shares Change (QoQ) 0.21% Owned by Institutions (%) 4.13% Shares Floating 3.95M Failed to Deliver (FTD) Shares 224 FTD / Avg. Volume 0.53%
Short Selling Information The latest short interest is 140.26K, so 2.27% of the outstanding
shares have been sold short.
Short Interest 140.26K Short % of Shares Out 2.27% Short % of Float 7.05% Short Ratio (days to cover) 5.44
Valuation Ratios The PE ratio is -5.35 and the forward
PE ratio is -12.21.
Monopar Therapeutics's PEG ratio is
-0.01.
PE Ratio -5.35 Forward PE -12.21 PS Ratio 0 Forward PS 358.9 PB Ratio 1.51 P/FCF Ratio -13.02 PEG Ratio -0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Monopar Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 11.47,
with a Debt / Equity ratio of 0.
Current Ratio 11.47 Quick Ratio 11.47 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.11M Employee Count 14 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 1749.79% in the
last 52 weeks. The beta is 1.22, so Monopar Therapeutics's
price volatility has been higher than the market average.
Beta 1.22 52-Week Price Change 1749.79% 50-Day Moving Average 38.31 200-Day Moving Average 34.66 Relative Strength Index (RSI) 65.28 Average Volume (20 Days) 42,251
Income Statement
Revenue n/a Gross Profit n/a Operating Income -16.16M Net Income -15.59M EBITDA -15.59M EBIT -15.59M Earnings Per Share (EPS) -4.11
Full Income Statement Balance Sheet The company has 45.82M in cash and 0 in
debt, giving a net cash position of 45.82M.
Cash & Cash Equivalents 45.82M Total Debt n/a Net Cash n/a Retained Earnings -75.79B Total Assets 53.87B Working Capital 52.16B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -6.4M
and capital expenditures 0, giving a free cash flow of -6.4M.
Operating Cash Flow -6.4M Capital Expenditures n/a Free Cash Flow -6.4M FCF Per Share -1.69
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields MNPR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for MNPR is $74,
which is 67.4% higher than the current price. The consensus rating is "Buy".
Price Target $74 Price Target Difference 67.4% Analyst Consensus Buy Analyst Count 8
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 13, 2024. It was a
backward
split with a ratio of 1:5.
Last Split Date Aug 13, 2024 Split Type backward Split Ratio 1:5
Scores Altman Z-Score -1.07 Piotroski F-Score 1
